{"id":"NCT01638000","sponsor":"Astellas Pharma Europe Ltd.","briefTitle":"A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.","officialTitle":"A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-12","primaryCompletion":"2013-04-24","completion":"2013-04-24","firstPosted":"2012-07-11","resultsPosted":"2016-08-30","lastUpdate":"2024-11-21"},"enrollment":1887,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Urologic Diseases","Urinary Bladder, Overactive","Urinary Bladder Diseases"],"interventions":[{"type":"DRUG","name":"Mirabegron","otherNames":["Betanis","YM178","Myrbetriq","Betmiga"]},{"type":"DRUG","name":"Solifenacin succinate","otherNames":["Vesicare","YM905","Vesikur","Vesitrim"]}],"arms":[{"label":"Mirabegron 50 mg","type":"EXPERIMENTAL"},{"label":"Solifenacin 5 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of efficacy.","primaryOutcome":{"measure":"Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours","timeFrame":"Baseline and final visit (up to Week 12)","effectByArm":[{"arm":"Mirabegron 50 mg","deltaMin":-2.95,"sd":0.087},{"arm":"Solifenacin 5 mg","deltaMin":-3.13,"sd":0.088}],"pValues":[{"comp":"OG000 vs OG001","p":"0.15"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":18},"locations":{"siteCount":217,"countries":["Armenia","Austria","Belarus","Belgium","Bulgaria","Canada","Czechia","Denmark","Finland","France","Georgia","Germany","Greece","Hungary","Ireland","Italy","Kazakhstan","Latvia","Lebanon","Lithuania","Netherlands","Norway","Poland","Portugal","Russia","Slovakia","Slovenia","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.astellasclinicalstudyresults.com/study.aspx?ID=27"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":936},"commonTop":["Dry mouth"]}}